{"company":{"id":3192810,"name":"MeiraGTx","domain":"meiragtx.com","url":"https://alion.io/company/meiragtx"},"answer":"As of Nov 18, 2026, Alion lists 10 companies most like MeiraGTx: PTC Therapeutics, BioMarin Pharmaceutical Inc., Vertex Pharmaceuticals, Sarepta, Intellia Therapeutics, Rocket Pharmaceuticals, Alnylam, Tessera Therapeutics, REGENXBIO and Genetixbiotx.","highlights":["MeiraGTx itself has 6 open roles on Alion.","Of them, Vertex Pharmaceuticals is hiring the most, with 227 open roles.","Tessera Therapeutics has raised the most venture funding on record: $230M.","Open roles at Alnylam fell the most: from 101 on Oct 19, 2026 to 92 now."],"as_of":"2026-11-18","cite":"Alion, \"MeiraGTx competitors and alternatives: 10 similar companies compared on hiring and funding\", as of Nov 18, 2026. https://alion.io/company/meiragtx/competitors","indexable":true,"target":{"name":"MeiraGTx","url":"https://alion.io/company/meiragtx","domain":"meiragtx.com","open_roles":6,"open_roles_change":null,"funding":{"total_raised_usd":null,"last_round":null,"last_round_usd":null,"last_round_date":null,"lead_investors":[]},"size_band":"201-500","headquarters":{"city":"New York","country":"US"},"technologies":["CAPA","GMP","GCP"],"hiring_countries":["GB","US"],"similarity":null},"competitors":[{"name":"PTC Therapeutics","url":"https://alion.io/company/ptcbio","domain":"ptcbio.com","open_roles":24,"open_roles_change":null,"funding":{"total_raised_usd":null,"last_round":null,"last_round_usd":null,"last_round_date":null,"lead_investors":[]},"size_band":"201-500","headquarters":{"city":"Warren","country":"US"},"technologies":["GCP","Good Clinical Practice","GMP"],"hiring_countries":["US","IE","GB"],"similarity":{"score":19.75,"shared_segments":["Rare Disease Therapeutics","Cell & Gene Therapy"],"shared_technologies":["Tableau","GCP","Power BI","PCR","ELISA"],"same_hq_country":true}},{"name":"BioMarin Pharmaceutical Inc.","url":"https://alion.io/company/biomarin-pharmaceutical-inc","domain":"biomarin.com","open_roles":57,"open_roles_change":null,"funding":{"total_raised_usd":null,"last_round":null,"last_round_usd":null,"last_round_date":null,"lead_investors":[]},"size_band":"501-1000","headquarters":{"city":"San Rafael","country":"US"},"technologies":["GMP","Microsoft Excel","CAPA"],"hiring_countries":["US","IE","GB"],"similarity":{"score":17.8,"shared_segments":["Rare Disease Therapeutics","Cell & Gene Therapy"],"shared_technologies":["Python","SQL","Tableau","Power BI","Machine Learning"],"same_hq_country":true}},{"name":"Vertex Pharmaceuticals","url":"https://alion.io/company/vrtx","domain":"vrtx.com","open_roles":227,"open_roles_change":null,"funding":{"total_raised_usd":null,"last_round":null,"last_round_usd":null,"last_round_date":null,"lead_investors":[]},"size_band":"5000+","headquarters":{"city":"Boston","country":"US"},"technologies":["GCP","AI Agents","Python"],"hiring_countries":["US","GB","NL"],"similarity":{"score":17.02,"shared_segments":["Rare Disease Therapeutics","Cell & Gene Therapy"],"shared_technologies":["Python","SQL","Tableau","GCP","Power BI"],"same_hq_country":true}},{"name":"Sarepta","url":"https://alion.io/company/sarepta","domain":"sarepta.com","open_roles":9,"open_roles_change":null,"funding":{"total_raised_usd":null,"last_round":null,"last_round_usd":null,"last_round_date":null,"lead_investors":[]},"size_band":"501-1000","headquarters":{"city":"Cambridge","country":"US"},"technologies":["GCP","Veeva","GLP"],"hiring_countries":["US"],"similarity":{"score":17,"shared_segments":["Rare Disease Therapeutics","Cell & Gene Therapy"],"shared_technologies":["GCP","ELISA","GMP","GLP","CAPA"],"same_hq_country":true}},{"name":"Intellia Therapeutics","url":"https://alion.io/company/intelliatx","domain":"intelliatx.com","open_roles":5,"open_roles_change":null,"funding":{"total_raised_usd":null,"last_round":null,"last_round_usd":null,"last_round_date":null,"lead_investors":[]},"size_band":"501-1000","headquarters":{"city":"Cambridge","country":"US"},"technologies":["Mandiant capa","Digital Twin","GMP"],"hiring_countries":["US"],"similarity":{"score":16.7,"shared_segments":["Cell & Gene Therapy","Rare Disease Therapeutics"],"shared_technologies":["Python","Tableau","GCP","Power BI","Mandiant capa"],"same_hq_country":true}},{"name":"Rocket Pharmaceuticals","url":"https://alion.io/company/rocketpharma","domain":"rocketpharma.com","open_roles":8,"open_roles_change":null,"funding":{"total_raised_usd":null,"last_round":null,"last_round_usd":null,"last_round_date":null,"lead_investors":[]},"size_band":"201-500","headquarters":{"city":"Cranbury","country":"US"},"technologies":["CAPA","GMP","PCR"],"hiring_countries":["US"],"similarity":{"score":16.65,"shared_segments":["Cell & Gene Therapy","Rare Disease Therapeutics"],"shared_technologies":["Machine Learning","PCR","ELISA","HPLC","GMP"],"same_hq_country":true}},{"name":"Alnylam","url":"https://alion.io/company/alnylam","domain":"alnylam.com","open_roles":92,"open_roles_change":{"since":"2026-10-19","from":101,"to":92,"pct":-9},"funding":{"total_raised_usd":null,"last_round":null,"last_round_usd":null,"last_round_date":null,"lead_investors":[]},"size_band":"1001-5000","headquarters":{"city":"Cambridge","country":"US"},"technologies":["Python","GCP","CAPA"],"hiring_countries":["US","DE","GB"],"similarity":{"score":16.22,"shared_segments":["Cell & Gene Therapy","Rare Disease Therapeutics"],"shared_technologies":["Python","SQL","Tableau","GCP","Power BI"],"same_hq_country":true}},{"name":"Tessera Therapeutics","url":"https://alion.io/company/tesseratherapeutics","domain":"tesseratherapeutics.com","open_roles":3,"open_roles_change":null,"funding":{"total_raised_usd":230000000,"last_round":"venture","last_round_usd":230000000,"last_round_date":"2021-05-20","lead_investors":[]},"size_band":"51-200","headquarters":{"city":"Somerville","country":"US"},"technologies":["GCP","Dagster","AWS"],"hiring_countries":["US"],"similarity":{"score":15.7,"shared_segments":["Rare Disease Therapeutics","Cell & Gene Therapy"],"shared_technologies":["GCP","HPLC","GMP"],"same_hq_country":true}},{"name":"REGENXBIO","url":"https://alion.io/company/regenxbio","domain":"regenxbio.com","open_roles":15,"open_roles_change":null,"funding":{"total_raised_usd":null,"last_round":null,"last_round_usd":null,"last_round_date":null,"lead_investors":[]},"size_band":"51-200","headquarters":{"city":"Rockville","country":"US"},"technologies":["SQL","CI/CD","Git"],"hiring_countries":["US"],"similarity":{"score":15.5,"shared_segments":["Cell & Gene Therapy","Rare Disease Therapeutics"],"shared_technologies":["Python","SQL","Tableau","Power BI","Machine Learning"],"same_hq_country":true}},{"name":"Genetixbiotx","url":"https://alion.io/company/genetixbiotx-2","domain":"genetixbiotx.com","open_roles":9,"open_roles_change":null,"funding":{"total_raised_usd":null,"last_round":null,"last_round_usd":null,"last_round_date":null,"lead_investors":[]},"size_band":"51-200","headquarters":{"city":"Somerville","country":"US"},"technologies":["CAPA","Microsoft Excel","Veeva"],"hiring_countries":["US"],"similarity":{"score":15.5,"shared_segments":["Cell & Gene Therapy","Rare Disease Therapeutics"],"shared_technologies":["Power BI","ELISA","HPLC","GMP","CAPA"],"same_hq_country":true}}],"method":"Ranked by Alion's similar-companies engine (the MCP tool similar_companies): shared industry segments and the overlap of the two segment sets, technologies named in both companies' job postings, the same headquarters country, a size band near it. Open roles are the visible postings on Alion today; their change is shown only for boards that state posting dates.","html_url":"https://alion.io/company/meiragtx/competitors","json_url":"https://alion.io/company/meiragtx/competitors.json","license":"CC BY-SA 4.0","meta":{"source":"Alion","built_at":"2026-11-18T02:50:30Z","generated_at":"2026-11-18T20:07:57Z"}}